Cardiovascular Systems Enrolls First Subject in ECLIPSE Coronary Clinical Trial

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

March 28, 2018

Cardiovascular Systems, Inc., in partnership with Cardiovascular Research Foundation (CRF), announces the first subject enrolled in its ECLIPSE coronary clinical trial.

Cardiovascular Systems notes the subject was treated by Dr. Richard Shlofmitz, an interventional cardiologist and the Director of the Department of Cardiology at St. Francis Hospital, Roslyn, NY. Dr. Shlofmitz also treated subjects in CSI’s ORBIT II and COAST clinical studies.

“Severely calcified coronary lesions have continued to grow in complexity while treating coronary artery disease (CAD),” Dr. Shlofmitz said. “The Diamondback 360® Coronary Orbital Atherectomy System (OAS) provides a novel treatment option for these patients compared to conventional angioplasty. Definitive data from the ECLIPSE clinical trial will guide my treatment approach for these difficult-to-treat patients.”

ECLIPSE is a prospective, multi-center, randomized clinical trial of approximately 2,000 subjects with severely calcified coronary lesions in the United States. Half the participants will receive orbital atherectomy prior to DES implantation, while the other half will receive conventional angioplasty, including specialty balloons, followed by DES implantation. The trial is powered to demonstrate differences in the primary endpoints of post-procedural minimal cross-sectional area (assessed by intravascular imaging in a subset of up to 400 patients) as well as in the clinical outcome of target vessel failure at one year. ECLIPSE will also evaluate key health economic outcomes.

“Many of us feel that coronary atherectomy is underutilized, particularly given the increasing complexity of lesions and patients seen in current-day interventional practice,” said Dr. Ajay Kirtane, the Director of the Cardiac Catheterization Laboratories at New York-Presbyterian/Columbia University Irving Medical Center, and one of the principal investigators of the ECLIPSE trial. Approximately 12 percent of coronary lesions are calcified, and current estimates suggest that atherectomy is only used in approximately 3 percent of coronary interventions. Dr. Kirtane added, “ECLIPSE is the largest randomized clinical trial to date expressly designed to assess the utility of adjunctive coronary atherectomy for calcific CAD.”

Said Dr. Philippe Généreux, co-principal investigator of the trial, interventional cardiologist at Morristown Medical Center, NJ, and the Director of the Angiographic Core Laboratory at the CRF Clinical Trials Center, “Coronary calcification has been shown to increase procedural difficulty and adverse events following conventional percutaneous coronary intervention (PCI). The use of orbital atherectomy has the ability to significantly modify lesion morphology, enabling successful stent delivery to help optimize stent expansion and apposition. This supports why we are randomizing to conventional angioplasty, toward the goal of ultimately improving PCI outcomes. The value of this trial is that it will inform physicians regarding the most effective treatment protocols and strategies for treating patients with calcific CAD.”

“Our commitment to clinical rigor continues to be a cornerstone in advancing our leadership in atherectomy,” said Scott Ward, President and CEO of Cardiovascular Systems. “The ECLIPSE trial is another important scientific step in demonstrating that the Diamondback 360® Coronary OAS will broaden physicians’ ability to safely and effectively treat more challenging CAD patients.”

CSI’s Diamondback 360® Coronary OAS is the first and only atherectomy device approved to specifically treat severely calcified coronary arteries. Since FDA approval on October 21, 2013, over 25,000 devices have been used to treat patients with CAD.



Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.